Know Cancer

or
forgot password

EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood


N/A
18 Years
N/A
Open (Enrolling)
Both
Lung Cancer

Thank you

Trial Information

EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood


OBJECTIVES:

- Examine the mutational status of the EGFR pathway in tumor and blood samples from
patients with lung cancer.

- Correlate the EGFR pathway mutations in these samples with clinical outcomes of these
patients.

OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway
mutations in DNA.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed lung cancer

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- May have received prior EGFR inhibitors

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Mutational status of the EGFR pathway

Safety Issue:

No

Principal Investigator

Philip C. Mack, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of California, Davis

Authority:

Unspecified

Study ID:

CDR0000583056

NCT ID:

NCT00899405

Start Date:

May 2005

Completion Date:

Related Keywords:

  • Lung Cancer
  • lung cancer
  • Lung Neoplasms

Name

Location

University of California Davis Cancer CenterSacramento, California  95817